These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27582872)

  • 1. Mediastinal dysgerminoma complicating pregnancy.
    Manikandan K; Veena P; Elamurugan S; Soundararaghavan S
    Obstet Med; 2012 Sep; 5(3):135-7. PubMed ID: 27582872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A favorable maternal and neonatal outcome following chemotherapy with etoposide, bleomycin, and cisplatin for management of grade 3 immature teratoma of the ovary.
    Ghaemmaghami F; Abbasi F; Abadi AG
    J Gynecol Oncol; 2009 Dec; 20(4):257-9. PubMed ID: 20041106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy].
    Ishibashi M; Nakayama K; Oride A; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):513-7. PubMed ID: 19295284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
    Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PVB chemotherapy in patients with recurrent or advanced dysgerminoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group.
    Pawinski A; Favalli G; Ploch E; Sahmoud T; van Oosterom AT; Pecorelli S
    Clin Oncol (R Coll Radiol); 1998; 10(5):301-5. PubMed ID: 9848330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma.
    Brewer M; Gershenson DM; Herzog CE; Mitchell MF; Silva EG; Wharton JT
    J Clin Oncol; 1999 Sep; 17(9):2670-75. PubMed ID: 10561340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
    Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
    Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
    Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H
    Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat.
    Marcon L; Hales BF; Robaire B
    J Androl; 2008; 29(4):408-17. PubMed ID: 18296477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian dysgerminoma with massive metastases to para-aortic lymph nodes.
    Takemori M; Ichimura T; Nishimura R; Hasegawa K
    Gynecol Obstet Invest; 2000; 49(3):211-3. PubMed ID: 10729765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
    Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
    Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report.
    Calzas Rodríguez J; Carmen Juarez Morales MD; Casero MA
    Respir Med Case Rep; 2016; 18():48-50. PubMed ID: 27330950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late recurrence in ovarian dysgerminoma with successful response to standard adjuvant chemotherapy: a case report and review of the literature.
    Jeyakumar A; Cabeza R; Hindenburg A
    Gynecol Oncol; 2001 May; 81(2):314-7. PubMed ID: 11330968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of a 2-day BEP regimen in postsurgical adjuvant chemotherapy of ovarian germ cell tumors.
    Tay SK; Tan LK
    Int J Gynecol Cancer; 2000 Jan; 10(1):13-18. PubMed ID: 11240646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
    Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
    J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trisomy 21 associated with ovarian dysgerminoma.
    Smucker JD; Roth LM; Sutton GP; Hurteau JA
    Gynecol Oncol; 1999 Sep; 74(3):512-4. PubMed ID: 10479522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.